Serum uric acid to creatinine ratio and metabolic syndrome in postmenopausal Chinese women

Jing Tao, PhD, Xin Shen, MD, Jie Li, MD, Erdenbat Cha, MD, Pei-Pei Gu, MD, Jun Liu, MD, Wei Zhu, MD, Lin-Long He, MD, Guo-Qing Li, MD, PhD, Zhao Wang, PhD

Abstract
This study aimed to investigate the association between Serum Uric Acid (UA) to Creatinine (Cr) Ratio (UA/Cr) and metabolic syndrome (MetS) in postmenopausal women.

A total of 455 patients with MetS and 457 age- and gender-matched controls were included in the present retrospective study. Serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), Cr, and UA were measured. We employed logistic regression analysis to investigate the association between serum UA/Cr and MetS in postmenopausal women.

Serum UA/Cr levels were significantly higher in patients with MetS than that in control subjects (P < .05). In the correlation analysis, serum UA/Cr showed a significantly positive correlation with age, hypertension, systolic pressure (SBP), diastolic pressure (DBP), waist, body mass index (BMI), TG, UA and negative correlation with type 2 diabetes mellitus (T2DM) and Cr (P all < .001). Moreover, multivariate analysis revealed that serum UA/Cr was still an independent risk factor for MetS (OR = 2.928, 95% CI = 2.385–3.596, P < .001) after adjustments for other confounders.

Serum UA/Cr are strongly associated with the risk of MetS in postmenopausal Chinese women.

Abbreviations: BMI = body mass index, Cr = creatinine, DBP = diastolic pressure, FPG = fasting plasma glucose, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, MetS = Metabolic syndrome, NHANES I = National Health and Nutrition Examination Survey, SBP = systolic pressure, T2DM = type 2 diabetes mellitus, TC = total cholesterol, TG = triglycerides, UA/Cr = serum uric acid to creatinine ratio.

Keywords: creatinine, metabolic syndrome, postmenopausal, uric acid

1. Introduction
Metabolic syndrome (MetS) is a cluster of metabolic disorders including abdominal obesity, raised blood pressure, high triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C) and hyperglycemia.[11] As a major worldwide public health problem, the prevalence of MetS has grown markedly over the past decades.[2–4] In China, the age-standardized prevalence of MetS was 9.8% in men and 17.8% in women in 2001, and the figures have increased to 31.0% in men and 36.8% in women in 2010.[5] It has been demonstrated that MetS is associated with the increasing mortality of type 2 diabetes mellitus (T2DM), cardiovascular disease and various other causes.[6–9] Postmenopausal women have an increased risk of MetS and epidemiological studies showed that prevalence of MetS is significantly higher in postmenopausal women too.[10–13]

Uric Acid (UA) is the final product of purine metabolism and is mainly eliminated in the urine.[14] Serum uric acid (SUA) level does represent an important risk factor for cardiovascular disease.[15] It has been demonstrated that SUA level is closely related to conditions such as obesity, endothelial dysfunction, oxidative metabolism, impaired glucose metabolism, platelet adhesiveness and hypertension.[16–18] In the First National Health and Nutrition Examination Survey (NHANES I) study in USA, a total of 5926 subjects were enrolled to investigate the association of SUA level with cardiovascular mortality and the result showed that increased SUA levels are independently and significantly associated with risk of cardiovascular mortality in an average of 16.4 years of follow-up.[19] Franse et al performed a cohort study in a randomized trial in 4327 patients with isolated systolic hypertension and found that SUA independently predicts cardiovascular events in older persons with isolated systolic hypertension.[20] Furthermore, in the community-based population of the Cardiovascular Health Study performed by Ekandayo et al, SUA level was associated with an increased risk of incident...
heart failure and each 1 mg/dL increasing in SUA level was associated with a 12% increasing in incident heart failure (HR = 1.12, P = .006). Serum creatinine (Cr) is a commonly used indicator of kidney decline. Evidences have demonstrated that Serum Cr was associated with the increased risk of T2DM, hypertension, obesity and CAD.\(^{[22]}\) Recently, renal function-normalized SUA (UA/Cr) has appeared as a new biomarker and is considered to reflect endogenous UA levels more precisely than SUA level. Several studies have suggested that serum UA/Cr ratio was significantly associated with chronic obstructive pulmonary disease, chronic kidney disease, β-Cell function in type 2 diabetes mellitus patients.\(^{[23–25]}\) However, there are limited studies focused on the relationship between serum UA/Cr ratio and MetS. The aim of the present study was to investigate the association between serum UA/Cr ratio and MetS in Chinese postmenopausal women.

2. Methods

2.1. Study subjects

All patients with MetS and control subjects were recruited from the People’s Hospital of Xinjiang Uygur Autonomous Region from 2016 to 2018. A total of 453 patients with MetS and 457 age- and gender-matched controls were included in the present retrospective study. MetS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria.\(^{[26]}\) In detail, the definition of MetS requires the presence of any 3 or more of the following 5 abnormalities:

1. elevated waist circumference: ≥90 cm in men or ≥80 cm in women;
2. systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or established treatment of already diagnosed hypertension;
3. elevated TG: ≥1.7 mmol/L or on drug treatment for elevated TG;
4. reduced HDL-C: <1.03 mmol/L in men or <1.37 mmol/L in women or on drug treatment for reduced HDL-C; and
5. abnormal fasting plasma glucose: ≥5.6 mmol/L or on drug treatment for elevated glucose. This study was approved by the Ethics Committee of the People’s Hospital of Xinjiang Uygur Autonomous Region (Urumqi, China).

2.2. Risk factors and definitions

In order to get a complete medical history, information on anthropometric measurements and blood biochemical examination were performed in all participants. Data on age, gender, systolic blood pressure, diastolic blood pressure, Waist, body mass index (BMI), smoking status, drinking status, T2DM, Serum concentrations of total cholesterol (TC), TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), Cr and UA were collected. Hypertension was defined as a systolic blood pressure of ≥140 mmHg and/or a diastolic blood pressure of ≥90 mmHg in at least 2 measurements or use of any antihypertensive drug. Diabetes mellitus was defined as 2 FPG level ≥ 7.0 mmol/l or a prior diabetes diagnosis and/or using a diabetes drug. Smoking was defined as current smoking. Drinking was defined as alcohol consumption ≥2 times per week. BMI was calculated as the weight in kilograms divided by the square of the height in meters (kg/m²).

2.3. Laboratory analysis

Peripheral venous blood samples of the patients were obtained for the assessment of routine laboratory parameters after 12-hour fasting. Laboratory tests were performed at the core laboratory of the People’s Hospital of Xinjiang Uygur Autonomous Region. TC, TG, HDL-C, LDL-C, uric acid, and creatinine levels were directly measured using the homogeneous enzymatic colorimetric assay (Roche Diagnostics) on an automatic analyzer (Cobas 8000).

2.4. Statistical analysis

All statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) 17.0 software package (SPSS Inc, Chicago, IL). Continuous variables were presented as the mean ± standard deviation (SD) and were compared using an independent samples t test. Categorical variables were expressed as numbers and percentages and were analyzed using chi-square tests. Relationships between serum UA/Cr and other variables were tested by Pearson correlation analysis. Logistic regression analyses were used to investigate potential factors associated with MetS and components of MetS. All statistical tests were 2-sided, and statistical significance was determined at P < .05.

3. Results

3.1. Clinical characteristics of the study population

A total of 912 subjects were recruited in the present study. The mean age of the study population was 62.41 ± 7.58. All participants were divided into MetS and control group according to the presence or absence of MetS. The baseline clinical characteristics of 453 MetS patients and 457 control subjects were shown in Table 1. BMI, Waist, FPG, TG, TC, UA and prevalence of hypertension and T2DM were more likely to be higher in patients with MetS than that in control subjects (P all < .05). Serum UA/Cr were also more likely to be higher in patients with MetS than that in control subjects (P < .001) (Fig. 1). While, HDL-C, LDL-C and SCr were more likely to be lower in patients with MetS than that in control subjects (P all < .05).

3.2. Correlations between serum UA/Cr and other variables

In the correlation analysis, serum UA/Cr showed a significantly positive correlation with age (r = 0.189, P < .001), hypertension (r = 0.247, P < .001), SBP (r = 0.273, P < .001), DBP (r = 0.225, P < .001), Waist (r = 0.310, P < .001), BMI (r = 0.271, P < .001), TG (r = 0.065, P = 0.499), UA (r = 0.647, P < .001). In addition, serum UA/Cr also showed a significantly negative correlation with Diabetes (r = −0.075, P = .023), serum Cr (r = −0.430, P < .001) (Table 2).

3.3. Multivariable logistic regression analyses of the major confounding factors for MetS

After the multivariate adjustments for the confounders, such as age, hypertension, smoking, drinking, BMI, waist, glucose, TC, TG, HDL-C and LDL-C, serum UA/Cr was still an independent
Baseline clinical characteristics of the study population.

| Parameters            | Overall (912) | Metabolic Syndrome (455) | Controls (457) | P    |
|-----------------------|---------------|--------------------------|----------------|------|
| Age, yr               | 62.41 ± 7.58  | 62.77 ± 7.31             | 62.04 ± 7.84   | .146 |
| Hypertension, n (%)   | 560 (61.40%)  | 329 (72.1%)              | 232 (50.8%)    | <.001|
| T2DM, n (%)           | 86 (9.43%)    | 69 (15.2%)               | 17 (3.7%)      | <.001|
| Smoking, n (%)        | 31 (3.40%)    | 20 (4.4%)                | 11 (2.4%)      | .008 |
| Drinking, n (%)       | 5 (0.5%)      | 3 (0.7%)                 | 2 (0.4%)       | .65  |
| SBP, mmHg             | 142.02 ± 19.64| 146.55 ± 18.51           | 137.49 ± 20.10 | <.001|
| DBP, mmHg             | 88.54 ± 16.00 | 92.07 ± 15.16            | 85.01 ± 16.06  | <.001|
| Waist (cm)            | 88.83 ± 10.43 | 90.86 ± 8.02             | 86.81 ± 11.41  | <.001|
| BMI, kg/m²             | 25.73 ± 3.49  | 26.33 ± 3.43             | 25.14 ± 3.45   | <.001|
| Glucose, mmol/L       | 5.39 ± 1.77   | 5.89 ± 0.12              | 4.89 ± 1.12    | <.001|
| TG, mmol/L            | 1.68 ± 1.03   | 2.03 ± 1.13              | 1.32 ± 0.78    | <.001|
| TC, mmol/L            | 4.93 ± 1.10   | 5.07 ± 1.16              | 4.80 ± 1.03    | <.001|
| HDL-C, mmol/L         | 1.24 ± 0.48   | 1.10 ± 0.42              | 1.38 ± 0.48    | <.001|
| LDL-C, mmol/L         | 2.81 ± 0.88   | 2.73 ± 0.84              | 2.90 ± 0.91    | .005 |
| UA, mmol/L            | 298.23 ± 74.46| 313.09 ± 76.89           | 283.44 ± 68.93 | <.001|
| Cr, mmol/L            | 63.88 ± 15.35 | 60.77 ± 13.49            | 66.97 ± 16.43  | <.001|
| UA/Cr                 | 4.80 ± 1.28   | 5.29 ± 1.35              | 4.52 ± 1.00    | <.001|

Continuous variables are expressed as mean ± SD. Categorical variables are expressed as percentages.

The P value of the continuous variables was calculated by the independent samples t test. The P value of the categorical variables was calculated by χ² test.

Risk factor for MetS (OR = 2.928, 95% CI = 2.385–3.596, P < .001) (Table 3).

3.4. Multivariable logistic regression analyses of the major confounding factors for the components of MetS

The multinomial variable was recoded into 5 categories: Central obesity, Hypertriglyceridemia, Low HDL-Cholesterol, Hypertension, and Hyper-glucose. The independent variables were age, hypertension, smoking, drinking, BMI, waist, glucose, TG, TC, HDL-C, LDL-C, and serum UA/Cr. After the multivariate adjustments for the confounders, UA/Cr was still an independent risk factor for central obesity and hypertension (OR = 2.122, 95% CI = 1.687–2.669, P < .001; OR = 1.899, 95% CI = 1.570–2.296, P < .001) (Table 4).

4. Discussion

In the present study, we investigated associations between serum UA/Cr ratio and MetS in postmenopausal women. Our results showed that serum UA/Cr ratio was higher in patients with MetS when compared with controls. There was a positive association between the increase in serum UA/Cr ratio and the prevalence of MetS. In addition, our results also showed that serum UA/Cr ratio was independently associated with MetS susceptibility even after adjustment for other baseline parameters. To the best of our knowledge, this is the first study to demonstrate the association of serum UA/Cr ratio and MetS in postmenopausal women.

Postmenopausal status is associated with an increased incidence of MetS. Epidemiological and clinical studies have shown...
shown that MetS is more relevant to postmenopausal women than premenopausal ones. Ricardo et al performed a cross-sectional study in pre- and postmenopausal women and found that the prevalence of MetS was 9.4% in premenopausal women and 22.2% in postmenopausal women.[27] Data from the Third National Health and Nutrition Examination Survey suggested that MetS was an independent risk factor for all-cause mortality, cardiovascular mortality, cardiac mortality and non-cardiovascular mortality in the subgroup of postmenopausal women. At the same time, the hazard ratio was also stronger in postmenopausal women. Further studies have demonstrated that the oxidative changes induced by hyperuricemia in adipocytes is a key in causing the metabolic syndrome in obese mice.[34]

The association between SUA and MetS has long been recognized. In a meta-analyses involving 54,970 participants and 8719 MS cases, elevated SUA levels led to an increased risk of MetS and were consistent with a linear dose-response relationship.[29] Yadav et al performed a population-based cohort study in 1590 healthy adults aged 40 to 70 years, and found that SUA may predicted as a risk factor for developing MetS during a mean of 2.6 years of follow-up.[30] Yang et al performed a prospective study of 3857 subjects who were free of MetS and found that hyperuricemia was an independent risk factor for MetS. The following description may explain the mechanisms that link SUA to MetS.

The association between SUA and MetS components have significantly negative correlation with T2DM. The reason may be better representative of endogenous serum uric acid and may be better correlated with metabolic diseases. In the present study, we found that serum UA/Cr was significantly higher in MetS patients than that in controls. After the multivariate adjustments for the confounders, serum UA/Cr was still an independent risk factor for MetS. The following description may explain the mechanisms that link SUA to MetS. First, Hyperuricemia may lead to the impaired of endothelial function and decreased release of nitric oxide from endothelial cells. While, the uptake of glucose in skeletal muscle is partly depended on the increasing blood flow which are mediated by the release of nitric oxide from endothelial cells. Therefore, UA may exacerbate insulin resistance by inhibiting the bioavailability of nitric oxide.[32–33] The second mechanism may be the inflammation and oxidative stress caused by SUA. Previous studies have demonstrated that the oxidative changes induced by hyperuricemia in adipocytes is a key in causing the metabolic syndrome in obese mice.[34]

The association between SUA and all MetS components have been studied in other studies. In the present study, we found that serum UA/Cr was still an independent risk factor for central obesity and hypertension after the multivariate adjustments for the confounders. The mechanism is still unclear, but insulin resistance induced by hyperuricemia is considered to be associated with the development of these metabolic disorders. In addition, we also found that serum UA/Cr showed a significantly negative correlation with T2DM. The reason may

Table 3
Logistic Regression Analysis for Metabolic Syndrome.

| Component | Univariate | | | Multivariate | | |
|-----------|------------|-----------|-----------|------------|-----------|-----------|
|           | OR         | 95% CI    | P value   | OR         | 95% CI    | P value   |
| Age       | 1.013      | 0.996–1.030 | <.001 | 0.979      | 0.952–1.007 | <.001 |
| Hypertension | 2.505      | 1.903–2.927 | <.001 | 3.188      | 2.516–3.822 | <.001 |
| Smoking   | 1.864      | 0.883–3.937 | <.001 | 2.427      | 0.750–7.854 | <.001 |
| Drinking  | 1.51       | 0.251–9.079 | .653 | 1.959      | 0.090–42.592 | .669 |
| BMI       | 1.106      | 1.064–1.150 | <.001 | 1.003      | 0.923–1.090 | .938 |
| Waist     | 1.04       | 1.026–1.053 | <.001 | 1.056      | 1.026–1.087 | <.001 |
| Glucose   | 1.721      | 1.502–1.973 | <.001 | 2.413      | 1.973–2.952 | <.001 |
| TG        | 2.804      | 2.267–3.438 | <.001 | 5.853      | 4.220–8.116 | <.001 |
| TC        | 1.256      | 1.110–1.422 | <.001 | 0.997      | 0.825–1.204 | .973 |
| HDL-C     | 0.182      | 0.124–0.266 | <.001 | 0.052      | 0.029–0.096 | <.001 |
| LDL-C     | 0.806      | 0.694–0.936 | <.001 | 0.097      | 0.072–1.156 | .430 |
| UA/Cr     | 2.064      | 1.801–2.366 | <.001 | 2.928      | 2.385–3.596 | <.001 |

BMI = Body mass index, HDL-C = high density lipoprotein-cholesterol, LDL-C = low density lipoprotein-cholesterol, TC = total cholesterol, TG = triglyceride.

Table 4
Logistic regression analysis for the components of metabolic syndrome.

| Component            | Univariate | | | Multivariate | | |
|----------------------|------------|-----------|-----------|------------|-----------|-----------|
|                      | OR         | 95% CI    | P value   | OR         | 95% CI    | P value   |
| Central obesity      | 2.631      | 2.150–3.219 | <.001 | 2.122      | 1.687–2.669 | <.001 |
| UA/Cr                | 0.001      | 0.809–1.003 | .056 | 0.978      | 0.867–1.104 | .721 |
| Hypertriglyceridemia | 1.052      | 0.944–1.173 | .358 | 1.129      | 0.999–1.275 | .051 |
| UA/Cr                | 2.361      | 1.964–2.838 | <.001 | 1.899      | 1.570–2.296 | <.001 |
| Hypertension         | 1.028      | 0.919–1.151 | .629 | 1.096      | 0.968–1.240 | .148 |
| Hyper-glucose        | 2.296      | 1.469–3.515 | <.001 | 2.319      | 1.598–3.330 | <.001 |

UA/Cr, a function-normalized SUA index, is considered to be.
be that long-term chronic hyperglycemia in patients with T2DM promotes high filtration state, and resulting in increased excretion of uric acid by kidney.\textsuperscript{135}

Several limitations should be considered in this study. First, we only draw conclusions based on the present cross-sectional study, it is difficult to get a cause-and-effect relationship between serum UA/Cr and MetS. Second, we do not take dietary habits into consideration as we do not have sufficient information. But dietary habits can affect serum uric acid levels. Additional studies need to be undertaken to clarify the underlying molecular mechanism that associates serum UA/Cr with MetS.

5. Conclusion

The present study revealed that serum UA/Cr ratio was significantly higher in MetS patients than that in controls. After the multivariate adjustments for the confounders, serum UA/Cr was still an independent risk factor for MetS.

Acknowledgments

We thank all of the participants for their contribution to this study.

Author contributions

Formal analysis: Jing Tao, Guo-Qing Li, Zhao Wang.
Methodology: Xin Shen, Jie Li, Lin-long He.
Validation: Jing Tao, Erdenbat Cha, Pei-Pei Gu.
Writing – original draft: Jing Tao.
Writing – review & editing: Jun Liu, Wei Zhu.

References

[1] Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629–36.
[2] Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–9.
[3] Aguilar MI, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015;313:1973–4.
[4] Lowre D, Mauvais-Jarvis F. Trends in prevalence of the metabolic syndrome. JAMA 2015;314:950.
[5] Lu J, Wang L, Li M, et al. Metabolic syndrome among adults in China: the 2010 China noncommunicable disease surveillance. J Clin Endocrinol Metab 2017;102:507–15.
[6] Sengul C, Cevik C, Ozveren O, et al. Echocardiographic epicardial fat thickness is associated with carotid intima-media thickness in patients with metabolic syndrome. Echocardiography 2011;28:833–8.
[7] Ismaa B, Almgren P, Tuom I, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–9.
[8] Mottillo S, Filson KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113–12.
[9] Chen Q, Zhang Y, Dung D, et al. Metabolic syndrome and its individual components with mortality among patients with coronary heart disease. Int J Cardiol 2016;224:8–14.
[10] Hesdari R, Sadeghi M, Talaei M, et al. Metabolic syndrome in menopausal transition: isfahan healthy heart program, a population based study. Diabetol Metab Syndr 2010;2:59.
[11] Jouyandeh Z, Nayebezhad F, Qorbani M, et al. Metabolic syndrome and menopause. J Diabetes Metab Disord 2013;12:1.
[12] Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2003;365:1398–405.
[13] Cho GJ, Lee JH, Park HT, et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause 2008;15:524–9.
[14] Feng D, Uric acid-a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009;18:526–30.
[15] Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta 2018;484:150–63.
[16] Richette P, Perez-Ruiz F, Doherty M, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 2014;10:654–61.
[17] Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729–41.
[18] Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol 2016;213:4–7.
[19] Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study,1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404–10.
[20] Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;20:1149–54.
[21] Ekundayo OJ, Dell’Italia LJ, Sanders PW, et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol 2010;142:279–87.
[22] Fried LF, Shipkag MG, Grump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003;41:1364–72.
[23] Durmus Kocak N, Sasaki G, Aka Akterur, et al. Serum uric acid levels and uric acid/creatinine ratios in stable chronic obstructive pulmonary disease (COPD) patients: are these parameters efficient predictors of patients at risk for exacerbation and/or severity of disease? Med Sci Monit 2016;22:4169–76.
[24] Al-Daghir NM, Al-Attas OS, Wani K, et al. Serum uric acid to creatinine ratio and risk of metabolic syndrome in Saudi type 2 diabetic patients. Sci Rep 2017;7:12104.
[25] Li M, Gu L, Yang J, et al. Serum uric acid to creatinine ratio correlates with β-cell function in type 2 diabetes. Diabetes Metab Res Rev 2018;34:e3001.
[26] Grundy SM, Cleeman JL, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.
[27] Marchi R, Dell’Agnolo CM, Lopes TCR, et al. Prevalence of metabolic syndrome in pre- and postmenopausal women. Arch Endocrinol Metab 2017;61:160–6.
[28] Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. Arthr Res Ther 2008;10:B116.
[29] Yuan H, Yu C, Li X, et al. Serum uric acid levels and incident metabolic syndrome in a Korean ruralcohort. J Hypertens 2015;33:1729–41.
[30] Yang T, Chu CH, Bai CH, et al. Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis 2012;220:525–31.
[31] Khosla UM, Zharkov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739–42.
[32] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2003;359:1811–21.
[33] Sautin YY, Nakagawa T, Zharkov S, et al. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007;293:C864–96.
[34] Facchini F, Chen YDI, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008–11.